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23; HAS: 28; G-BA: 11; IQWiG: 11) covering 31 oncology drugs were reviewed. Thirteen 
(42%) of these drugs had ≥ 1 PRO claims in their European label; corresponding HTA 
submissions also included PROs. Manufacturers presented PROs in 67.1% (57/85) of 
HTA submissions (BC: 72.7%; NSCLC: 100%; PaC: 0%; PC: 77.3%; leukemias: 43.5%). 
PROs were also presented in the HTA submissions of 8 drugs with no EMA PRO data. 
In HTA submissions, PROs assessing QoL (51/57, 89.4%) and pain (18/57, 31.6%) were 
the most common. Statistical significance was observed in 59.6% of the 52 submis-
sions with available results. In the final HTA decision, PROs were mentioned for 
43.9% of submissions, not mentioned in 35.1% and were not reviewed by the HTA 
body in 21.0% of submissions due mainly to methodological issues. ConClusions: 
Demonstrating a statistically significant improvement in PROs does not increase 
the chance of a positive HTA recommendation (65.5% vs 74.1% for submissions 
without PROs). The value that PRO claims in oncology have to payers needs to be 
further clarified.
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DeveloPmeNt of A PAtieNt-RePoRteD outCome (PRo) AssessmeNt of 
CoRe NoN-smAll Cell luNg CANCeR (NsClC) symPtoms
DeBusk K1, Johnson N2, Evans C2, Sandler A1, Ramalingam SS3, Campbell A1
1Genentech, South San Francisco, CA, USA, 2Endpoint Outcomes, Boston, MA, USA, 3Emory 
University, Atlanta, GA, USA
objeCtives: Lung cancer is the leading cause of cancer-related mortality world-
wide. Patients experience symptoms throughout the course of their disease which 
detrimentally affect their health-related quality of life (HRQOL). The assessment 
and monitoring of changes in NSCLC symptoms is increasingly important in clini-
cal trials when making treatment comparisons between therapies. The objective 
was to develop a brief assessment of core symptoms appropriate for use in clini-
cal trials. Methods: This non-interventional, cross-sectional qualitative study 
consisted of conducting individual interviews with NSCLC patients. Patients aged 
≥ 18 years with stage IIB-IV NSCLC participated in individual interviews to provide 
descriptions of NSCLC symptoms, including severity, frequency and change over 
time. Results: 17 treatment-naïve patients (mean age= 68yrs) were recruited for 
concept elicitation interviews. The most common spontaneously reported symp-
toms of NSCLC were cough (58.8%), shortness of breath (47.1%), chest pain (47.1%) 
and fatigue (29.4%). These symptoms were included in the initial 12-item version 
of the Symptoms In Lung Cancer (SILC) scale. An additional 10 post-treatment 
patients (mean age= 63yrs) participated in cognitive interviews to ensure that the 
items were correctly interpreted, relevant, and disease-related (i.e., not treatment-
related). They overall found the SILC easy to complete and interpreted most of 
the items as intended. Items related to fatigue were removed as post-treatment 
patients found these concepts difficult to attribute to their disease, and were 
reported by less than a third of treatment-naïve patients. The final 9-item SILC 
uses a 5-point verbal response scale (higher scores indicating greater severity/
frequency), a 7-day recall period, and assesses 3 core symptom concepts: chest 
pain (severity and frequency), cough (severity and frequency), dyspnea (while 
lying down/sitting, standing, walking, carrying a light load and when walking up 
an incline). ConClusions: SILC is an easy-to-use and concise tool to assess the 
core symptoms of disease in NSCLC patients.
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CANCeR is AssoCiAteD With iNtRAoPeRAtive AND PostPRoCeDuRAl 
ComPliCAtioNs AND DisoRDeRs
Engelhard J1, Jockwig A2, Kostev K1
1IMS Health, Frankfurt am Main, Germany, 2Fresenius University of Applied Sciences, Idstein, 
Germany
objeCtives: The risk of nocosomial infections plays important role especially for 
patients with severe sicknesses and lenghty hospital stays. To better understand 
associated risk factors, real world evidence data from primary care patients was 
analyzed. Methods: 5,817 primary care patients from 982 general practices (GP) 
with first diagnosis of intra- or postoperative complications (“IPC”) (in digestive sys-
tem (ICD 10: K91) or circulatory system (ICD 10: I97)) were identified during the index 
period 04/2010-03/2015 from the Disease Analyzer database, Germany). Furthermore, 
5,817 controls were included after individual matching (1:1) to study cases on age, 
gender, type of health insurance (private or statutory) and the physician. Results: 
Study patients in both groups were 64 yrs old on average, 3% were female. The share 
of patients with cancer diagnosis was higher in the case than in the control group 
(21.5% versus 5.8%, p< 0.001), e.g. significant differences were identified in shares of 
breast cancer (7.3% versus 1.0%, p< 0.001) or cancer of digestive organs (8.4% versus 
0.9%, p< 0.001). There were no significant differences in the shares of prostate, skin 
and respiratory organ cancer. In multivariate regression models, newly diagnosed 
IPC were significantly associated with cancer (Odds ratio, OR, 95%CI: 4.58, 4.03-5.20), 
as well as with breast cancer (8.51, 6.41-11.29) and cancer of digestive organs (10.49, 
7.87-14.00) among others. ConClusions: This study suggests that cancer diagnosis 
might be a risk factor for the development of ICP. More specifically, certain tumors, 
like breast cancer or cancer of digestive organs are more likely to be associated with 
ICP than others (e.g. prostate or skin cancer). Potential reasons for this observa-
tions, e.g. differences in therapy duration or frequency and complexity of surgical 
procedures, have to be investigated.
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myeloPRolifeRAtive NeoPlAsm symPtom AssessmeNt foRm - totAl 
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objeCtives: Symptom burden is critical for assessing therapeutic efficacy in 
myelofibrosis, characterized by splenomegaly, abdominal and constitutional 
they were completing it at their outpatient clinic. Such data collection must be tied 
to a transparent clinical purpose that patients see as an integral part of their health 
care. Other avenues for collecting outpatient drug toxicities outcomes should be 
investigated.
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the use of soCiAl meDiA to geNeRAte heAlth DAtA foR effeCtiveNess 
ReseARCh: A sCoPiNg RevieW
Kalf R1, Makady A1, Meijboom K1, Goettsch W2
1The National Healthcare Institute (ZIN), Diemen, The Netherlands, 2National Healthcare Institute 
(ZiN), Diemen, The Netherlands
objeCtives: Explore the use of social media for health data collection in effective-
ness research in oncology. Methods: We conducted a systematic review of scien-
tific literature to assess health data collected via social media. Literature published 
in PubMed between January 2010 and April 2015 was included. Three reviewers 
screened studies for eligibility and extracted data. Based on included articles an 
explanatory and qualitative analysis was performed. Results: Initially the search 
strategy identified 580 articles. Study inclusion criteria were met by 12 articles 
based on title and abstract, and by 4 articles based on the full paper. Two additional 
articles were included after evaluating the reference lists of included hits. Of the 6 
included articles, four focused on identifying side effects to cancer treatments by 
using patient forum websites, one assessed the feasibility of disseminating a qual-
ity of life survey via a Facebook support group, and one focused on methodological 
considerations in analyzing data from Twitter. Several benefits of health data gener-
ated via social media were discussed, such as the ability to provide additional infor-
mation on (unlabelled) side effects, the recruitment of a small sample of patients 
spread over a relatively wide geographic area, and the possibility to capture patient 
perspectives that tend to be more difficult to measure in clinical trials. Limitations 
of using social media to generate health data included validating authenticity of 
posts and users, duplicate and multiple posts, the volume of data available, selec-
tion bias (e.g. sicker or older patients may not be represented on social media) and 
incompleteness of data on patient characteristics. ConClusions: Limited litera-
ture is available on the actual use of health data from social media in effectiveness 
research in oncology. However, the potential of health data collected via social media 
is of increasing interest in the scientific community and should be further explored.
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the imPACt of NoN-musCle iNvAsive BlADDeR CANCeR: QuAlitAtive 
ReseARCh With PAtieNts
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objeCtives: To understand disease-related symptoms experienced by high-risk 
non-muscle invasive bladder cancer (NMIBC) patients, selected treatment patterns, 
patient satisfaction with their treatment and concern regarding future potential 
treatments. Methods: Ten interviews were conducted with patients recruited at 
two urology clinics in the United States; patients were recruited by clinic staff. 
Patients were eligible to participate if they met one of the following three criteria: 
1) were Bacillus Calmette–Guérin (BCG)-naïve treated with transurethral resection 
of bladder tumor (TURBT) ± intravesical chemotherapy; 2) had current or previous 
BCG treatment but were refractory or resistant to treatment; or 3) were BCG refrac-
tory or relapsing and whose next treatment option would be cystectomy but were 
prior to cystectomy. Results: Participants were demographically representative 
of the patient population that seeks treatment for NMIBC. Nearly all interview par-
ticipants reported visible hematuria as the symptom which led to their diagnosis. 
Other disease-specific symptoms were not frequently reported. All participants had 
received one or more NMIBC drugs (i.e., BCG, mitomycin, valrubicin), a procedure 
(i.e., TURBT, cystoscopy), or both. All participants reported transient medication 
side effects (e.g., painful urination, urgency, frequency) and/or catheter or stent 
adverse events (e.g., painful or burning urination, passing blood clots) following their 
procedure or surgery. Despite these findings, almost all participants were satisfied 
with their treatment. All patients were concerned about the possibility of cystec-
tomy, should their disease progress, and were highly motivated to avoid this treat-
ment. ConClusions: Patients reported disease and treatment-related symptoms; 
however, they were not severe enough to impact the patient’s willingness to undergo 
intravesical therapy or diagnostic procedures. Further research is needed to better 
characterize the impact of timing and duration of treatment-related symptoms, as 
well as patient and caregiver perspective on additional bladder cancer therapies, 
especially when bladder sparing may be warranted.
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Do PAtieNt RePoRteD outComes (PRo) iN oNCology mAtteR iN heAlth 
teChNology AssessmeNts (htA)?
Casamayor M1, Palazzolo D2, Gubbels L3, Moïse P4, Wijnands T3, Mantuano M5,  
Ivanescu C3
1Quintiles, Barcelona, Spain, 2Quintiles, Reading, UK, 3Quintiles Advisory Services, Hoofddorp, The 
Netherlands, 4Quintiles, Levallois-Perret, France, 5Quintiles, Cassina de’ Pecchi (Milano), Italy
objeCtives: In parallel with increasing requests for PROs to be assessed in oncology 
trials, the European Medicine Agency (EMA) in 2014 published a reflection paper 
outlining their recommendations. The value PRO claims have to HTA Agencies is less 
clear. Our objective was to assess whether HTA agencies placed a similar valuation 
on PROs as the EMA. Methods: Our focus was HTA agencies in key 3 European 
countries: Germany, the UK and France Cancer types were selected where they had 
a high number of HTA assessments: breast cancer (BC), non-small cell lung cancer 
(NSCLC), pancreatic cancer (PaC); prostate cancer (PC) and leukaemias. Relevant 
HTA appraisals since January 2013 were identified using Quintiles’ proprietary 
HTA Accelerator database. The drugs evaluated were compared to their respective 
European labels. Results: Overall, 85 HTA submissions (AWMSG: 5; NICE: 7; SMC: 
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heAlth-RelAteD QuAlity of life AND tReAtmeNt sAtisfACtioN 
AmoNg PAtieNts ReCeiviNg Novel ANti-ANDRogeN theRAPies foR the 
tReAtmeNt of metAstAtiC CAstRAte-ResistANt PRostAte CANCeR 
(mCRPC)
Dearden L1, Shalet N2, Artenie C3, Mills A3, Gater A4, Grant L4, Jackson C3
1Janssen EMEA HEMAR, High Wycombe, UK, 2Janssen, High Wycombe, UK, 3Adelphi Research UK, 
Bollington, UK, 4Adelphi Values Ltd, Bollington, UK
objeCtives: Abiraterone acetate and enzalutamide, novel anti-androgen therapies 
with distinct modes of action for the treatment of metastatic castration-resistant 
prostate cancer (mCRPC), are approved in both the pre-chemotherapy and post-
chemotherapy settings. These anti-androgen therapies have significantly improved 
outcomes among mCRPC patients. However, to date there is little published evidence 
regarding patients’ real-world experience of these therapies in both the pre-chem-
otherapy or post-chemotherapy settings, particularly in terms of health-related 
quality of life (HRQoL) and treatment satisfaction. Methods: Qualitative face-to-
face interviews were conducted with mCRPC patients (n= 38) and carers (n= 12) to 
obtain in-depth data concerning the patient experience with novel anti-androgen 
therapy. This included patients with experience of abiraterone acetate or enzalu-
tamide in either the pre-chemotherapy or post-chemotherapy setting in France, 
Germany and the UK. Findings from this study have been used to inform the design 
of a larger quantitative, multinational online survey to further explore and quantify 
HRQoL and treatment satisfaction among mCRPC patients receiving anti-androgen 
therapy. Results: Patients generally had high expectations at initiation of ther-
apy with a primary emphasis on reduction in prostate-specific antigen levels and 
improvements in HRQoL. Patients and carers reported that experiences on treat-
ment had met or exceeded expectations. Administration procedures appeared to 
be of limited concern for patients and only mentioned by patients when prompted 
by directive questions. In particular, the need to take abiraterone acetate on an 
empty stomach was not deemed problematic. Some differences in the patient 
experience (e.g. side effects) and HRQoL of patients receiving abiraterone acetate 
and enzalutamide were noted and warrant further exploration. ConClusions: 
Patients and carers reported largely positive experiences with novel anti-androgen 
therapies for the treatment of mCRPC. Potential differences between regimens in 
terms of treatment satisfaction and HRQoL are currently being explored in a larger 
quantitative online study.
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ReDuCiNg the BARRieRs to CAPtuRiNg PAtieNt RePoRteD outComes iN 
oNCology stuDies
Thilaganathan JA, O’Donohoe P
CRF Health, London, UK
objeCtives: The FDA has previously noted that data reported directly by patients 
about how they are feeling and functioning (i.e. patient reported outcomes (PROs)) 
are rarely included in oncology drug labelling claims in the United States, with 
end points relating to survival, imaging and biomarkers tending to take priority. 
However, while research suggests an increase in PRO use in oncology trials, signifi-
cant challenges remain and a low burden solution for all stakeholders is becom-
ing increasingly important. Methods: Key challenges for integrating PROs into 
oncology clinical trials were identified based on study protocols, sponsor feedback 
and best practices from previous oncology studies. Based on this feedback an elec-
tronic solution for capturing data in oncology studies was developed. Results: 
Patient and site burden were identified as key challenges in oncology studies 
deploying PROs. Oncology patients can be very impaired, so requiring the com-
pletion of lengthy questionnaires can result in non-compliance. A user focused 
electronic system reduces the burden of patients providing answers to question-
naires, and opens the possibility for data capture to occur at home rather than at 
study visits. Feedback also highlighted that sites struggle with organizing visits 
and staying protocol compliant. An electronic visit scheduling tool can help sites 
keep track of what order and at which visits questionnaires should be completed 
and to help remind and reschedule patient visits. ConClusions: Obtaining a 
proper understanding of the patients experience in oncology clinical studies is 
increasingly becoming a priority for multiple stakeholders, not least the patients 
themselves. While there is evidence that the number of PROs being included in 
oncology studies is increasing over time there are still significant challenges to 
capturing high-quality PRO data. A holistic electronic solution, which considers 
both the patients and sites experience of providing data, can reduce the barriers 
to capturing high-quality PRO data.
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oNCology? A CAse stuDy iN metAstAtiC CAstRAte ResistANt PRostAte 
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objeCtives: Research on adherence, health outcomes and shared decision mak-
ing all highlight the importance of understanding patient treatment preferences. 
However, a recent systematic review (Shingler et al., 2014) showed how little work 
has explored treatment preferences of oncology patients. The aim of the present 
study was to identify issues from previous patient preference research in oncology 
to design a novel protocol to explore treatment preferences of men with metastatic 
prostate cancer. Methods: It was hypothesised that the low number of reported 
studies in oncology may be due to methodological issues encountered in studies. 
A review of stated preference research completed in oncology identified different 
issues. This information was then used to design a protocol for a patient prefer-
ence study in men with metastatic castrate resistant prostate cancer. Results: 
Identified issues include (i) the use of inappropriate attributes (describing death, 
survival or progression), (ii) challenges with recruitment, sometimes associated 
symptoms, often painful and debilitating (Mughal et al. 2014). Developed from 
the widely used MPN-SAF, the 7-item MPN-SAF TSS was modified with word-
ing changes and by adding one tiredness item to better meet regulatory needs 
and assess symptom severity in myelofibrosis to support treatment benefit end-
points in clinical research. Study objectives were to translate the mMPN-SAF TSS 
into 21 languages for 26 countries and to assess comprehension and concep-
tual equivalence with the English source version in order to expand its use in 
global myelofibrosis research. Methods: The mMPN-SAF TSS was translated 
following ISPOR guidelines for linguistic validation of PRO measures (Wild et 
al., 2005) using the universal approach (Wild et al., 2009). For each non-English 
language, two forward translations by native translators, reconciliation of for-
ward translations, back-translation by one English-speaker fluent in the target 
language, and final reconciliation by a native-speaking language coordinator 
were conducted. Harmonization (i.e., comparison between languages for con-
sistent interpretation) was performed to ensure conceptual equivalence across 
languages. Interviews were conducted with 4-5 native-speaking myelofibrosis 
patients for each language/country combination (N= 142). Interview data were 
analyzed qualitatively to assess linguistic and cultural validity in each language 
and confirm conceptual equivalence. Results: Mean age was 60 years (range 
25-88); 51% were male. The translations were well understood and considered 
relevant with some patients raising minor issues during interviews. Patient 
feedback resulted in wording changes to the Bulgarian, Czech, Danish, Dutch, 
German, Hebrew, Hungarian, Japanese, Korean, Malay, Russian, Spanish, Simplified 
and Traditional Chinese versions. ConClusions: All translated versions of the 
mMPN-SAF TSS were confirmed to be conceptually equivalent and well understood 
in the 26 countries evaluated. These translations fill a significant need for patient-
focused instruments in local languages to facilitate future myelofibrosis research 
worldwide.
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the fiNNish veRsioNs of the loWeR-limB seCtioNs of the toRoNto 
extRemity sAlvAge sCoRe AND the musCuloskeletAl tumoR soCiety 
sCAle: A Pilot stuDy
Repo JP, Kask G, Barner-Rasmussen I, Blomqvist C, Tukiainen EJ
University of Helsinki and Helsinki University Hospital, Helsinki, Finland
objeCtives: The Finnish language has no no function-related cancer-specific 
outcome measures. The authors translated the Toronto Extremity Salvage Score 
(TESS) and the Musculoskeletal Tumor Society (MSTS) into Finnish and pilot tested 
the versions. Methods: Translation and transcultural adaptation was adhered to 
the guidelines of the International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR). Lower-limb TESS and MSTS outcome measures underwent 
forward-backward translation into Finnish. A multidisciplinary panel reviewed 
the process and proposed pre-final Finnish versions. Between March and May 
2015, altogether 18 consecutive patients who had undergone limb-sparing surgery 
for lower extremity soft tissue sarcoma (STS) visited the outpatient clinic of the 
Helsinki University Hospital Department of Oncology and completed the TESS, 
while simultaneously undergoing clinical assessment with the MSTS. Participants 
were interviewed to reveal problems in the translations. Results: The transla-
tion process revealed minor cultural differences between the translations of the 
TESS, which required adjustments. The MSTS translated well. After evaluating the 
measurement outcomes, the median TESS and MSTS scores were 85.5% (range, 
51.5-100.0%) and 76.7% (range, 26.7-100.0%), respectively. In both outcome meas-
ures, the authors noted a 5% ceiling effect. ConClusions: The pilot testing of the 
Finnish translation of the lower-limb TESS and MSTS indicated a good functional 
outcome in most patients who underwent lower limb-sparing surgery for STS. 
The TESS and the MSTS measurement outcomes correlated relatively closely. The 
psychometric properties of the Finnish versions of the lower-limb TESS and MSTS 
warrant further studying.
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BReAst CANCeR PAtieNts’ PeRCePtioN oN heAlth imPACts fRom 
ReCeiviNg ChemotheRAPy
Areepium N
Chulalongkorn University, Bangkok, Thailand
objeCtives: Receiving chemotherapy causes moderate to severe adverse events 
which deteriorate to both body and mind of breast cancer patients. Some ques-
tionnaires were developed to measure breast cancer patients’ quality of life e.g., 
the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-
C30, the Functional Assessment of Cancer Therapy for Breast cancer (FACT-B). 
Howereve, those questionnaires were rarely used in routine practice due to time 
consuming in difficulty in outcome evaluation. Therefore, we need to develop 
the practical questionnaire to evaluate impacts of chemotherapy on the overall 
health status in breast cancer patients’ view. Methods: We develop the ques-
tionnaire focusing on the symptoms related to adverse reaction of chemotherapy 
which patients felt and correlate with activity of daily living. The questionnaire 
consisted of 16 items for patients to answer with 5 likert scale (strongly disagree 
0 to strongly agree 4). The possible highest score were 64 and the higher score was 
the more suffering from chemotherapy in patients’ perspective. Results: One 
hundred breast cancer patients were interviewed. The average interview time was 
only 5-10 minutes per patient. Average age of patients were 52.09 ±12.77 years old 
and majority of them (71%) had stage I to III breast cancer. The average score was 
23.06 + 13.27 (minimum score was 0 and maximum score was 57 out of 64). we 
found the highest score (2.32 + 1.67) that patient reported for impacts on their 
heath from chemotherapy was “I am tried easier” and the lowest score (0.56 + 1.21) 
patient reported was “it is hard to breathe”. The factors associated with total score 
of questionnaire were adverse reactions. ConClusions: Our questionnaire can 
be used as a screening tool to classify patients according to severity and urgency 
for providing pharmaceutical care especially in the practice sites with limited 
manpower of clinical pharmacists.
